Provided by Tiger Trade Technology Pte. Ltd.

SAP SE ADRhedged

39.62
+0.04080.10%
Post-market: 39.620.00000.00%16:10 EDT
Volume:227
Turnover:9K
Market Cap:792.51K
PE:- -
High:39.74
Open:39.74
Low:39.62
Close:39.58
52wk High:51.57
52wk Low:27.49
Shares:20.00K
Float Shares:20.00K
Volume Ratio:0.39
T/O Rate:1.13%
Dividend:1.19
Dividend Rate:3.00%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

NYSE Most Active Issues

Dow Jones
·
Aug 15

SaverOne 2014 Ltd. Announces July 2026 Board Resignation of Director Douglas Davis

TIPRANKS
·
Aug 15

Nintendo Co. Ltd. ADR Outperforms Market on Strong Trading Day

Dow Jones
·
Aug 15

Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)

TIPRANKS
·
Aug 15

New York Closing Stocks

Dow Jones
·
Aug 15

Jianzhi Education Technology Launches $5.4 Million ADS Offering to Bolster Operations

TIPRANKS
·
Aug 14

Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Dow Jones
·
Aug 14

Mizuho Securities Remains a Buy on Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Aug 14

Anheuser-Busch InBev S.A. ADR Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

Ascentage Pharma Corrects Timing for August 19, 2026 Interim Results Webcast

TIPRANKS
·
Aug 13

Copel Board Approves R$706 Million Interest on Equity and 2025 Form 20-F Filing

TIPRANKS
·
Aug 13

Asian Companies Raise $28 Billion via ADRs in 2024, Marking a Six-Year High, as AI Boom and Valuation Gaps Drive Listings

Stock News
·
Aug 13

Anheuser-Busch InBev S.A. ADR Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Aug 13

New York Closing Stocks

Dow Jones
·
Aug 13

Stocks Ex-Dividend August 14

Dow Jones
·
Aug 13

Haleon’s New Gum‑Health Toothpaste Trial: What Investors Should Watch

TIPRANKS
·
Aug 13

Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Aug 12

Kaspi.kz Posts Strong H1 2026 Revenue Growth as Costs Hold Profit Flat

TIPRANKS
·
Aug 12

Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating

TIPRANKS
·
Aug 12

NYSE Net Change Percentage Gainers & Losers

Dow Jones
·
Aug 12